Ocugen, Inc. (OCGN) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to Ocugen's second quarter 2025 financial results and business update. Please note that this call is being recorded at this time. All participants' lines are in listen-only mode. Following the speaker's commentary, there will be a question and answer session. I'll now turn the call over to Tiffany Hamilton, Ocugen's head of corporate communications. You may begin. Thank you, Operator, and good morning, everyone. Joining me on today's call and webcast is Dr. Shankar Musunuri, Ocugen's chairman, CEO, and co-founder, who will provide a business update and an overview of our clinical and operational progress. Ramesh Ramachandran, our chief accounting officer, is also on the call to provide a financial update for the quarter ended June 30, 2025. Dr. Huma Kumar, chief medical officer, and Dr. Arun Upadhyay, chief scientific officer, will be available to answer questions following the presentation. This morning, we issued a press release detailing associated business and operational highlights for the second quarter of 2025. We encourage listeners to review the press release, which is available on our website at Ocugen.com. This call is being recorded, and a replay with the accompanying slide presentation will be available on the investor section of the Ocugen website for approximately 45 days. This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. which are subject to risks and uncertainties. We may, in some cases, use terms such as predicts, believes, potential, proposed, continue, estimates, anticipates, expects, plans, intends, may, could, might, will, should, or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements....